Clinical trials in Leiderdorp

41 clinical trials in Leiderdorp, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Leiderdorp at a glance

clinical trials

Paediatric trials0
Research sites1

Quick filters

41 trials in Leiderdorp

Open in trial search

Cardiac failure+1

Recruiting

Investigational

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:Novo Nordisk A/S

Contact Research Centre

Cardiac failure

Recruiting

Registered drug

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bi 690517
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Arteriosclerosis

Recruiting

Investigational

Effect of Lepodisiran on Coronary Plaque in Adults with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease or High Risk for First Event

Investigational

The Netherlands

Participants:18–64 years
Substances:Ly3819469 Sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Triple negative breast cancer

Recruiting

Registered drugNo placebo

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Secondary progressive multiple sclerosis

Recruiting

Investigational

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Remibrutinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Chronic kidney disease+1

Recruiting

Investigational

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:Eli Lilly & Co.

Contact Research Centre

Arteriosclerosis

Recruiting

InvestigationalNo placebo

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Pelacarsen
Sponsor:Novartis Pharma AG

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

Registered drugNo placebo

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:University Of Cologne

Contact Research Centre

Peripheral arterial occlusive disease+1

Recruiting

Registered drug

Study on Low-Dose Colchicine for Patients with Peripheral Artery Disease to Reduce Cardiovascular Risks

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Colchicine
Sponsor:Hamilton Health Sciences Corporation

Contact Research Centre

Cerebrovascular accident

Recruiting

Registered drugNo placebo

Study on Stopping or Continuing Clopidogrel, Carbasalate Calcium, and Dipyridamole for Young Patients After Stroke Without a Known Cause

Registered drugNo placebo

The Netherlands

Participants:18–64 years
Substances:Acetylsalicylic Acid
Sponsor:Stichting Radboud University Medical Center

Contact Research Centre

Embolism venous

Recruiting

Registered drugNo placebo

Study on Venous Thromboembolism Prevention with Enoxaparin Sodium and Drug Combination for Patients Undergoing Total Hip or Knee Replacement

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Andexanet Alfa
Sponsor:Leids Universitair Medisch Centrum (LUMC)

Contact Research Centre

Chronic kidney disease

Recruiting

Registered drug

Study on Dapagliflozin for Patients with Severe Chronic Kidney Disease to Improve Kidney and Heart Health Outcomes

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Dapagliflozin
Sponsor:Universitair Medisch Centrum Groningen

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Leiderdorp

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking studies focusing on cardiovascular disease prevention and treatment, including trials evaluating new therapies for heart failure and atrial fibrillation.

Lipoprotein management therapies
Heart failure treatments
Stroke prevention methods

Multiple innovative treatments being tested to reduce major cardiovascular events and improve patient outcomes.

02 Oncology Studies

Comprehensive research into various cancer treatments, with particular focus on breast cancer and colorectal cancer therapeutic approaches.

Advanced breast cancer treatments
Colorectal cancer therapies
Personalized treatment strategies

Studies evaluating novel drug combinations and treatment protocols for various stages of cancer.

03 Neurological Disorders

Innovative research focusing on multiple sclerosis treatment optimization and personalized dosing strategies.

MS treatment personalization
Drug interval optimization
Comparative therapy studies

Advanced trials exploring more effective and tailored treatment approaches for neurological conditions.

Back to the Netherlands All countries